[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643446":3},{"organization":4,"outcomesModule":7,"designInfo":54,"detailedDescription":65,"studyPopulation":53,"armGroups":66,"interventions":80,"overallOfficials":101,"centralContacts":106,"locations":115,"responsibleParty":135,"collaborators":53,"id":138,"slug":139,"hasResults":140,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":140,"sex":146,"minAge":147,"maxAge":148,"enrollmentInfo":149,"targetDuration":53,"studyType":152,"phases":153,"briefSummary":155,"conditions":156,"keywords":161,"overallStatus":117,"whyStopped":53,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":178},{"fullName":5,"class":6},"Mansoura University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":53},[9],{"measure":10,"description":11,"timeFrame":12},"Additional Uterotonic Requirement Within 24 Hours","Proportion of patients requiring at least one additional rescue uterotonic agent at any timepoint within 24 hours of delivery, based on clinical assessment of inadequate uterine tone or uterine atony by the attending obstetrician or anesthesiologist.","Within 24 hours of delivery",[14,18,22,26,29,32,36,39,42,46,50],{"measure":15,"description":16,"timeFrame":17},"Intraoperative Blood Loss - Gravimetric Method","Quantitative intraoperative blood loss measured by gravimetric method: weight of soaked materials minus dry materials divided by 1.05, plus suction volume, minus irrigation and amniotic fluid volumes.","Intraoperative - from cord clamping to skin closure",{"measure":19,"description":20,"timeFrame":21},"Total 24-Hour Blood Loss","Cumulative blood loss combining gravimetric intraoperative measurement and weighed postoperative lochia pads at 2 and 24 hours.","0 to 24 hours after delivery",{"measure":23,"description":24,"timeFrame":25},"Actual Blood Loss - Gross Formula","Calculated using estimated blood volume multiplied by the ratio of preoperative to postoperative hemoglobin change: ABL = EBV x (Hb preoperative minus Hb postoperative) divided by Hb preoperative, where EBV = body weight in kg x 85 mL\u002Fkg.","Preoperative baseline to 24 hours postoperatively",{"measure":27,"description":28,"timeFrame":25},"Hemoglobin Change","Change in venous hemoglobin concentration from preoperative baseline to 24 hours postoperatively, measured by automated complete blood count analyzer.",{"measure":30,"description":31,"timeFrame":25},"Hematocrit Change","Change in hematocrit from preoperative baseline to 24 hours postoperatively, measured by automated complete blood count analyzer.",{"measure":33,"description":34,"timeFrame":35},"Uterine Tone Score - Verbal Numerical Rating Scale","Uterine tone assessed by blinded obstetrician using 11-point Verbal Numerical Rating Scale (0 = completely atonic, 10 = maximally contracted) via bimanual palpation at three timepoints.","At 2, 5, and 10 minutes after carbetocin bolus",{"measure":37,"description":38,"timeFrame":12},"Postpartum Hemorrhage Incidence","Proportion of patients with total blood loss of 1000 mL or more within 24 hours of delivery, measured by gravimetric quantification.",{"measure":40,"description":41,"timeFrame":12},"Blood Transfusion Requirement","Proportion of patients receiving packed red blood cell transfusion and total units of packed red blood cells transfused.",{"measure":43,"description":44,"timeFrame":45},"Systolic Blood Pressure","Systolic blood pressure measured by non-invasive blood pressure cuff monitoring intraoperatively and in the postanesthesia care unit.","Every 2.5 minutes intraoperatively and every 15 minutes for 4 hours postoperatively",{"measure":47,"description":48,"timeFrame":49},"Heart Rate","Heart rate measured by continuous 5-lead electrocardiogram monitoring intraoperatively and in the postanesthesia care unit.","Continuous intraoperatively and every 15 minutes for 4 hours postoperatively",{"measure":51,"description":52,"timeFrame":12},"Adverse Effects Incidence","Incidence and severity of drug-related adverse effects including nausea, vomiting, facial flushing, headache, chest tightness, tachycardia, hypotension, and oliguria, documented by standardized checklist.",null,{"allocation":55,"interventionModel":56,"interventionModelDescription":57,"primaryPurpose":58,"observationalModel":53,"timePerspective":53,"maskingInfo":59},"RANDOMIZED","PARALLEL","Two parallel groups with 1:1 randomization. Group C receives carbetocin monotherapy (bolus plus placebo infusion). Group C+O receives carbetocin plus supplemental oxytocin infusion. Block randomization with variable block sizes of 4 and 6, stratified by parity.","TREATMENT",{"masking":60,"maskingDescription":53,"whoMasked":61},"TRIPLE",[62,63,64],"PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR","PHARMACOLOGICAL RATIONALE:\n\nCarbetocin exerts its uterotonic effect through sustained occupancy of myometrial oxytocin receptors (OTRs). Continuous stimulation of OTRs triggers homologous receptor desensitization, progressively reducing myometrial responsiveness. The addition of an oxytocin infusion following carbetocin raises three competing hypotheses: (1) incremental benefit from residual unoccupied receptors; (2) receptor counterproductivity through accelerated downregulation; or (3) pharmacological redundancy. No published RCT has resolved this uncertainty.\n\nTRIAL DESIGN:\n\nThe trial uses a non-inferiority design because the combination regimen is already practiced without evidence. Demonstrating non-inferiority of monotherapy would provide the first evidence to safely simplify uterotonic regimens, reduce drug costs, nursing workload, and unnecessary receptor stimulation.\n\nBLOOD LOSS MEASUREMENT:\n\nIntraoperative blood loss measured by gravimetric quantification: \\[Weight soaked materials minus Weight dry materials\\] divided by 1.05, plus suction canister volume, minus irrigation volume, minus amniotic fluid volume. Secondary measurement uses the Gross formula: ABL = EBV x (Hb preoperative minus Hb postoperative) divided by Hb preoperative, where EBV = body weight (kg) x 85 mL\u002Fkg.\n\nUTERINE TONE ASSESSMENT:\n\nAssessed using the 11-point Verbal Numerical Rating Scale (VNRS 0-10) with predefined anchor definitions, by the blinded operating obstetrician via bimanual palpation at 2, 5, and 10 minutes following carbetocin bolus. Pre-study inter-rater calibration session with intraclass correlation coefficient target of 0.80 or more.\n\nSTANDARDIZED FLUID PROTOCOL:\n\nAll patients receive a standardized intravenous fluid protocol to eliminate hemodilution as a confounding variable: spinal coload Ringer's Lactate 500 mL; intraoperative maintenance 100 mL\u002Fhour; study infusion 500 mL over 4 hours identical in both groups; postoperative Ringer's Lactate 80 mL\u002Fhour for 8 hours. Total 24-hour fluid volume recorded as a statistical covariate.\n\nSTATISTICAL ANALYSIS:\n\nNon-inferiority declared if the upper bound of the two-sided 95% confidence interval of the risk difference does not exceed +0.10. Both per-protocol and intention-to-treat analyses performed; concordance of both required per ICH E9(R1). IRB approval: Subcommittee of Health and Bioethics Research Ethics, Qassim University, Approval No. 26-23-4, dated June 02, 2026.",[67,74],{"label":68,"type":69,"description":70,"interventionNames":71},"Group C - Carbetocin Monotherapy","ACTIVE_COMPARATOR","Carbetocin 100 micrograms IV bolus over 1 minute immediately after cord clamping, followed by placebo infusion (500 mL 0.9% sodium chloride at 83 mL\u002Fhour over 4 hours). The infusion bag is visually identical to the active arm.",[72,73],"Drug: Carbetocin","Drug: Placebo Saline Infusion",{"label":75,"type":76,"description":77,"interventionNames":78},"Group C+O - Carbetocin Plus Oxytocin","EXPERIMENTAL","Carbetocin 100 micrograms IV bolus over 1 minute immediately after cord clamping, followed by active infusion (oxytocin 10 IU in 500 mL 0.9% sodium chloride at 83 mL\u002Fhour over 4 hours).",[72,79],"Drug: Oxytocin",[81,89,95],{"type":82,"name":83,"description":84,"armGroupLabels":85,"otherNames":86},"DRUG","Carbetocin","Carbetocin 100 micrograms (1 mL) IV bolus administered over 1 minute immediately after umbilical cord clamping. Identical administration in both arms.",[68,75],[87,88],"Duratocin","Pabal",{"type":82,"name":90,"description":91,"armGroupLabels":92,"otherNames":93},"Oxytocin","Oxytocin 10 IU added to 500 mL 0.9% sodium chloride, infused at 83 mL\u002Fhour over 4 hours, initiated within 2 minutes of carbetocin bolus. Administered in the combination arm only.",[75],[94],"Syntocinon",{"type":82,"name":96,"description":97,"armGroupLabels":98,"otherNames":99},"Placebo Saline Infusion","500 mL 0.9% sodium chloride infused at 83 mL\u002Fhour over 4 hours, initiated within 2 minutes of carbetocin bolus. Visually identical to the active oxytocin infusion. Administered in the monotherapy arm only.",[68],[100],"Normal Saline Placebo",[102],{"name":103,"affiliation":104,"role":105},"Mohamed A Tolba, MD","Qassim University Medical City","PRINCIPAL_INVESTIGATOR",[107,111],{"name":103,"role":108,"phone":109,"phoneExt":53,"email":110},"CONTACT","966507439018","m_atolba1234@mans.edu.eg",{"name":112,"role":108,"phone":113,"phoneExt":53,"email":114},"Omar S Al Misnid, MD9","966561205555","OMisnid@qumc.edu.sa",[116],{"facility":104,"status":117,"city":118,"state":119,"zip":120,"country":121,"countryCode":122,"cosmosGeoPoint":123,"geoPoint":128,"contacts":129},"RECRUITING","Buraidah","Al-Qassim Region","51452","Saudi Arabia","SA",{"type":124,"coordinates":125},"Point",[126,127],43.97497,26.32599,{"lat":127,"lon":126},[130,131,133],{"name":103,"role":108,"phone":109,"phoneExt":53,"email":110},{"name":132,"role":108,"phone":113,"phoneExt":53,"email":114},"Omar S Al Misnid, MD",{"name":134,"role":105,"phone":53,"phoneExt":53,"email":53},"Omar Saleh Al Misnid, MD",{"type":105,"investigatorFullName":136,"investigatorTitle":137,"investigatorAffiliation":5,"oldNameTitle":53,"oldOrganization":53},"Mohamed Ahmed Tolba","Consultant Anesthesiologist","100643446","phase-4-carbetocin-monotherapy-versus-carbetocin-plus-oxytocin-infusion-in-elective-cesarean-delivery-a-non-inferiority-trial-100643446",false,"NCT07636421","Carbetocin Monotherapy Versus Carbetocin Plus Oxytocin Infusion in Elective Cesarean Delivery: A Non-Inferiority Trial","Comparative Efficacy of Carbetocin Monotherapy Versus Carbetocin With Supplemental Oxytocin Infusion in Maintaining Uterine Tone and Preventing Blood Loss in Elective Cesarean Delivery: A Randomized, Double-Blind, Non-Inferiority Controlled Trial","CARBOXY-RCT","Inclusion Criteria:\n\n* Adult women aged 18 to 45 years\n* Scheduled for elective non-emergency cesarean delivery\n* Spinal anesthesia planned and administered as the sole anesthetic technique\n* Singleton pregnancy at gestational age of 37 completed weeks or more\n* ASA physical status II\n* Preoperative hemoglobin of 9 g\u002FdL or more\n* Able to provide written informed consent in Arabic or English\n\nExclusion Criteria:\n\n* Emergency or crash cesarean delivery\n* Placenta previa, placenta accreta spectrum disorder, or other abnormal placentation\n* Known uterine anomalies likely to impair contractility including fibroids greater than 5 cm, bicornuate or unicornuate uterus\n* Grand multiparity defined as 5 or more previous deliveries\n* Multiple gestation including twins or higher order\n* Polyhydramnios defined as amniotic fluid index greater than 24 cm\n* Prior oxytocin augmentation in current pregnancy for more than 6 hours\n* Known hypersensitivity to carbetocin, oxytocin, or any formulation excipient\n* Severe preeclampsia, eclampsia, or HELLP syndrome\n* Cardiovascular disease including arrhythmia, valvular disease, cardiomyopathy, or ischemic heart disease\n* Known coagulopathy or thrombocytopenia with platelets less than 100 x 10\\^9\u002FL\n* Hepatic or renal impairment\n* Body mass index greater than 40 kg\u002Fm2 at time of delivery\n* Enrollment in another interventional clinical trial","FEMALE","18 Years","45 Years",{"count":150,"type":151},332,"ESTIMATED","INTERVENTIONAL",[154],"PHASE4","Background: Carbetocin is an established single-dose uterotonic agent for postpartum hemorrhage prophylaxis at elective cesarean delivery. Despite its proven efficacy, many clinicians routinely add a supplemental oxytocin infusion following carbetocin administration without evidence-based justification. Concurrent oxytocin receptor stimulation may be redundant, counterproductive through receptor desensitization, or incrementally beneficial - a mechanistic uncertainty that remains unresolved in the published literature.\n\nObjectives: To determine whether carbetocin monotherapy (100 micrograms IV bolus plus placebo infusion) is non-inferior to carbetocin plus supplemental oxytocin infusion (10 IU over 4 hours) in preventing the need for additional uterotonic agents within 24 hours of elective cesarean delivery.\n\nStudy Design: Prospective, randomized, double-blind, placebo-controlled, non-inferiority trial with an integrated pilot phase. Phase 1 (Pilot, n=60) establishes local feasibility and event rate. Phase 2 (Full trial, n=332) provides the definitive non-inferiority analysis.\n\nParticipants: Women aged 18-45 years undergoing elective cesarean delivery under spinal anesthesia at Qassim University Medical City, singleton pregnancy at or beyond 37 weeks, ASA physical status II, preoperative hemoglobin 9 g\u002FdL or more.\n\nInterventions: Group C (Monotherapy): Carbetocin 100 micrograms IV bolus plus placebo saline infusion 500 mL over 4 hours. Group C+O (Combination): Carbetocin 100 micrograms IV bolus plus oxytocin 10 IU in 500 mL saline over 4 hours.\n\nPrimary Outcome: Proportion of patients requiring at least one additional uterotonic agent within 24 hours of delivery.\n\nSecondary Outcomes: Quantitative intraoperative blood loss by gravimetric measurement; total 24-hour blood loss; actual blood loss by Gross formula; hemoglobin and hematocrit changes; uterine tone scores by verbal numerical rating scale (0-10) at 2, 5, and 10 minutes; incidence of postpartum hemorrhage; blood transfusion requirement; hemodynamic profiles; adverse effects.\n\nSample Size: 332 patients (166 per group), non-inferiority margin 10 percentage points, one-sided alpha 0.025, 80% power, estimated baseline event rate 10%, with 15% dropout allowance.",[157,158,159,160],"Postpartum Hemorrhage","Uterine Atony","Cesarean Section","Blood Loss, Surgical",[83,90,162,163,164,165,166,167,168],"Uterotonic","Elective Cesarean Delivery","Non-Inferiority Trial","Uterine Tone","Gravimetric Blood Loss","Obstetric Anesthesia","Spinal Anesthesia","2026-10-06",{"date":171,"type":172},"2026-10-09","ACTUAL",{"date":174,"type":172},"2026-08-08",{"date":176,"type":151},"2028-08",{"name":5,"class":6},1]